Most trials involve individuals with advanced cancer, but at least one trial involved patients with colon adenomas at risk for colorectal cancer, demonstrating that high levels of anti-MUC1 IgG could be achieved with a MUC1-based vaccine except in individuals with evidence of pre-existing circulating myeloid-derived suppressor cells (106). This evidence concerns the gene MUC1 and colorectal cancer.